Breathlessness at rest is not the dominant presentation of patients admitted with heart failure

European Journal of Heart Failure

Volumn 16, Issue 12, 2014, Pages 1283-1291

  Shoaib, Ahmad ^a   Waleed, Mohammad ^a   Khan, Saima ^a   Raza, Ali ^a   Zuhair, Mohamed ^a   Kassianides, Xenophon ^a   Djahit, Ayse ^a   Goode, Kevin ^a   Wong, Kenneth ^a   Rigby, Alan ^a   Clark, Andrew ^a   Cleland, John ^a,b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Acute heart failure; Blood pressure; Congestion; Heart rate; Respiratory rate; Symptoms

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN T; CARDIOVASCULAR AGENT;

ACUTE HEART FAILURE; AGED; ARTICLE; BREATHING RATE; CARDIOVASCULAR MORTALITY; DYSPNEA; FEMALE; HEART FAILURE; HEART RATE; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; RETROSPECTIVE STUDY; SHORT OF BREATH AT REST; SYSTOLIC BLOOD PRESSURE; VITAL SIGN; BED REST; BLOOD PRESSURE; HOSPITALIZATION; LENGTH OF STAY; MECHANICAL VENTILATOR; MORTALITY; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BED REST; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; DYSPNEA; FEMALE; HEART FAILURE; HEART RATE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; OXYGEN INHALATION THERAPY; RESPIRATORY RATE; RETROSPECTIVE STUDIES; VENTILATORS, MECHANICAL;

EID: 84913540842     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.153     Document Type: Article

References (27)

1. McDonagh T, Cleland J, Dargie HJ, Whittaker T, Standing M, Mitchell M, Cunningham D,. National Heart Failure Audit April 2010-March 2011. National Institute For Cardiovascular Outcomes Research (NICOR); 2012.
2. Butler J, Fonarow GC, Gheorghiade M,. Strategies and opportunities for drug development in heart failure. JAMA 2013; 309: 1593-1594.
3. Clark AL, Cleland JG,. Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol 2013; 10: 156-170.
4. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M,. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005; 11: 200-205.
5. Shoaib A, Dicken B, Mabote T, Pellicori P, Torabi A, Clark A, Wong K, Cleland JG,. Checking-up on the National Audit on Heart Failure: are only a minority of patients admitted with heart failure truly breathless at rest and how many are suitable for Serelaxin? BCS Annual Conference 2013. London; 2013.
6. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Courtney D, Hasa J, Spinar J, Masip J, Frank Peacock W, Sliwa K, Gayat E, Filippatos G, Cleland JG, Gheorghiade M,. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010; 31: 832-841.
7. Shoaib A, Mabote T, Zuhair M, Kassianides X, Cleland J,. Acute heart failure (suspected or confirmed): initial diagnosis and subsequent evaluation with traditional and novel technologies. World J Cardiovasc Dis 2013; 3: 290-300.
8. Shoaib A, Kassianides X, Zuhair M, Waleed M, Goode K, Wong K, Cleland J, Clark A,. Severe breathlessness at rest is not the most important presentation of acute heart failure. J Am Coll Cardiol 2014; 63: 12S.
9. Cain KC, Lange NT,. Approximate case influence for the proportional hazards regression model with censored data. Biometrics 1984; 40: 493-499.
10. Sauerbrei W,. The use of resampling methods to simplify regression models in medical statistics. J R Stat Soc Ser C (Appl Stat) 1999; 48: 313-329.
11. Verweij PJM, Van Houwelingen HC,. Cross-validation in survival analysis. Stat Med 1993; 12: 2305-2314.
12. Ingle L, Rigby AS, Carroll S, Butterly R, King RF, Cooke CB, Cleland JG, Clark AL,. Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure. Eur Heart J 2007; 28: 560-568.
13. Concato J, Peduzzi P, Holford TR, Feinstein AR,. Importance of events per independent variable in proportional hazards analysis. I. Background, goals and general strategy. J Clin Epidemiol 1995; 48: 1495-1501.
14. Peduzzi P, Concato J, Feinstein AR, Holford TR,. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48: 1503-1510.
15. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR,. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206.
16. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M,. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
17. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J,. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463.
18. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO,. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013; 61: 391-403.
19. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB,. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-777.
20. Shoaib A, Shahid M, Zohair M, Waleed M, Djahit A, Kassianides X, Wong K, Rigby A, Cleland J, Clark A,. Is presentation of acute heart failure patients linked to mortality? Heart 2014; 100 Suppl 3:A34.
21. Pellicori P, Carubelli V, Zhang J, Castiello T, Sherwi N, Clark AL, Cleland JGF,. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC: Cardiovasc Imaging 2013; 6: 16-28.
22. Cleland J, Dargie H, Hardman S, Mcdonagh T, Mitchell P,. National Heart Failure Audit April 2012-March 2013 http://www.ucl.ac.uk/nicor/audits/heartfailure/additionalfiles/pdfs/annualreports/NHFA13medium.pdf.
23. Siirila-Waris K, Lassus J, Melin J, Peuhkurinen K, Nieminen MS, Harjola VP,. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006; 27: 3011-3017.
24. Fonarow GC,. Epidemiology and risk stratification in acute heart failure. Am Heart J 2008; 155: 200-207.
25. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, Gheorghiade M,. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010; 122: 1975-1996.
26. Nunez J, Nunez E, Robles R, Bodi V, Sanchis J, Carratala A, Aparici M, Llacer A,. Prognostic value of brain natriuretic peptide in acute heart failure: mortality and hospital readmission. Rev Esp Cardiol 2008; 61: 1332-1337.
27. Cowie MR, Collinson PO, Darige H, Hobbs FR, McDonagh TA, McDonald K, Rowell N,. Recommendations on the clinical use of B-type natriuretic peptide testing (BNP or NTproBNP) in the UK and Ireland. Br J Cardiol 2010; 17: 76-80.